World-Renowned Ophthalmologists to Highlight Benefits of MicroPulse® Technology in Treating Patients with Glaucoma and Retinal Diseases
MOUNTAIN VIEW, Calif., September 18, 2018 -- IRIDEX Corporation (Nasdaq:IRIX), a leading provider of innovative laser systems in ophthalmology, today announced they will be hosting a symposium at the Annual Meeting of the European Society for Cataract and Refractive Surgeons (ESCRS) in Vienna, Austria on September 22, 2018. MicroPulse® Technology: Latest Trends in Laser Treatment Choices for Glaucoma and Retinal Diseases will feature five world-renowned glaucoma and retina specialists who plan to share how they are using the Company’s MicroPulse technology. The one-hour session will feature multiple cases, results, and include time for audience questions.
Sandra Fernando Sieminski, MD, the Director of Glaucoma Service at the University of Buffalo in New York, USA, will be one of five presenters at the symposium. “Laser treatment for glaucoma has evolved significantly and many ophthalmologists do not recognize the wide variety of patients that may greatly benefit from treatment with IRIDEX’s MicroPulse P3 device. For example, in patients with moderate to severe disease, I have had great success with open angle, angle closure, and pseudoexfoliative glaucoma. At the symposium, my colleagues and I expect to share our data that highlights many of these new benefits,” states Dr. Sieminksi.
Matteo Forlini, MD, a vitreoretinal surgeon at Domus Nova Hospital in Ravenna, Italy, will also share his experiences at the symposium. “We continue to increase our understanding of the benefits of MicroPulse Laser Therapy in conjunction with anti-VEGF for the treatment of macular edema. I look forward to sharing my results in Vienna,” states Dr. Forlini.
The symposium will take place on Saturday, September 22 from 13:00-14:00 in room Lehar 2. The program is as follows:
13:00 – 13:02 - Marc Toeteberg (University Hospital Zurich, Switzerland)
13:02 – 13:12 - Matteo Forlini, MD (Domus Nova Hospital, Ravenna, Italy)
- Successful MicroPulse Treatment for Macular Edema in Retinal Vein Occlusion
13:12 – 13:22 - Boris Stanzel, MD, FEBO (Knappschaft Eye Hospital, Sulzbach, Germany)
- MicroPulse Laser Induced Macular Remodeling After ILM Peeling in Full Thickness Macular Holes
13:22 – 13:32 - Sandra Sieminski, MD (University at Buffalo, Buffalo, NY, USA)
- MicroPulse P3 Procedure for Various Glaucoma Patients: Going Beyond Late Stage Disease
13:32 – 13:42 - Marc Toeteberg, MD, FEBO (University Hospital Zurich, Switzerland)
- MicroPulse CPC Glaucoma Treatment and Patient’s Profiles: University of Zurich Experience
13:42 – 13:52 - K. Sheng Lim, MBChB, MD, FRCOphth (St Thomas' Hospital, United Kingdom)
- Updates from the MicroPulse Aqueous Dynamics Study in Early or moderate POAG
13:52 - 14:00 - Questions and Answers
In addition to the symposium, IRIDEX will be offering a “Speak with MicroPulse Experts” event at its booth (C501) every day between 10:30-11:30 and 14:00-15:00. Physicians will have the opportunity to speak with glaucoma or retina specialists about their experiences treating a wide variety of cases using IRIDEX lasers in MicroPulse mode.
Glaucoma is the second most common cause of blindness in the world, and surgical interventions are not always possible for certain patients. MicroPulse Cyclophotocoagulation (CPC) is a safe and effective treatment option for a variety of types of glaucoma, and it can be performed either in the operating room or as an outpatient, office-based procedure.
The ESCRS Congress anticipates welcoming over 7,500 ophthalmologists from 130 countries in Vienna, Austria. The meeting takes place from September 22-26 at the Messe Wien Exhibition and Congress Center. Registration for the MicroPulse symposium can be completed at www.iridex.com/escrs.
About IRIDEX
IRIDEX is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.
Media Contact:
Jamie Hall
Pascale Communications, LLC.
724.417.0167
pr@iridex.com
Investor Relations
Lynn Pieper Lewis or Leigh Salvo
415.937.5404
investors@iridex.com